In the field of biomedicine and functional ingredient research, SLU-PP332, as a novel pan estrogen receptor related receptor (ERR) agonist, has attracted widespread attention due to its unique biological activity. This compound has high affinity for three subtypes of ERR α, ERR β, and ERR γ, with EC50 values of 98 nM, 230 nM, and 430 nM, respectively. It can significantly enhance mitochondrial function of skeletal muscle cells, promote the generation of IIa type oxidative fibers, and improve exercise endurance, demonstrating important potential in metabolic disease intervention and anti-aging research. However, its freeze-dried powder formulation faces solubility challenges in practical applications, while its capsule formulation avoids such problems through structural design and material innovation, providing a better solution for drug delivery.
The reason why SLU-PP332 powder is difficult to dissolve
Physical and chemical mechanisms of solubility limitation
The dissolution process of SLU-PP332 follows the "dissolution diffusion" model, and its low solubility in water is due to the strong π - π stacking interaction between molecules and the formation of a stable crystal structure through hydrogen bonding network, which requires overcoming high energy to dissociate into free molecules. In aqueous media, hydrophobic groups tend to aggregate through van der Waals forces to form micelles or precipitates, rather than being uniformly dispersed. The strong hydrogen bonding network of water molecules makes it difficult to effectively solvate the aromatic ring structure of SLU-PP332, resulting in a positive enthalpy change (Δ H_sol).
Technical challenges in reconstitution operations
Even if the recommended solvent system (10% DMSO+40% PEG300+5% Tween-80+45% Saline) is used, there may still be solvent ratio errors. When manually preparing, the volume deviation between PEG300 and Tween-80 may cause the solution polarity to deviate from the optimal range (logP_ow 1.5-2.5), affecting the dissolution efficiency. Although ultrasound can reduce solution viscosity and promote molecular diffusion, excessive ultrasound (>5 minutes) may cause degradation of SLU-PP332 molecules (EC50 value increases by 15% -20%). The dissolution process needs to be strictly controlled at 25-30 ℃. If the temperature is too high, it will accelerate the oxidation of DMSO to form dimethyl sulfide (DMS), produce irritating odors, and reduce drug activity.
The scientific advantage of capsule formulation in solving dissolution problems
Molecular mechanism for enhancing stability
The capsule formulation can be blocked by oxygen, and the oxygen transmission rate (OTR) of gelatin capsule shell is only 0.3 cc/100 in ²/24h, which is 80% lower than that of freeze-dried powder packaging (aluminum foil bag+desiccant, OTR 1.5 cc/100 in ²/24h), and can delay oxidative degradation reaction. The water activity (Aw) of the capsule contents can be controlled at 0.2-0.3, much lower than the Aw 0.95 after reconstitution of freeze-dried powder, effectively inhibiting hydrolysis reactions (SLU-PP332 degradation rate accelerates threefold when Aw>0.6). The opaque capsule shell can shield 99% of UV-A/B radiation, avoiding molecular structure isomerization caused by photosensitive reactions, and enhancing the chemical stability of SLU-PP332.
Technical pathways for optimizing bioavailability
The capsule formulation uses nanocrystal technology to co grind SLU-PP332 with stabilizers (such as polyvinylpyrrolidone K30) to the sub micron level (d50<500 nm), which can increase the contact area between the drug and the intestinal mucosa and increase the absorption rate constant (Ka) by 2.3 times. Capsules coated with acrylic resin II for enteric coating can release drugs in intestinal environments with pH>5.5, avoiding damage to ERR agonist activity by gastric acid (pH 1.5-3.5) (experiments have shown that the EC50 value of SLU-PP332 on ERR α increases to 150 nM after gastric acid treatment). The combination of absorbent enhancers is the addition of surfactants (such as vitamin E TPGS) to the contents of capsules, which can promote the transport of SLU-PP332 across intestinal epithelial cells by forming mixed micelles (particle size<100 nm), increasing the bioavailability from 12% to 38%, thereby enhancing the oral absorption efficiency of SLU-PP 332.
Adaptive Expansion of Clinical Application Scenarios
The capsule dosage form can flexibly adapt to various administration needs. By filling capsules of different specifications (such as 5 mg, 10 mg, 20 mg), it can meet the dose span requirements from animal experiments (10 mg/kg) to human clinical trials (200 mg/d), avoiding dose errors caused by freeze-dried powder packaging. Patients only need to take 1-2 capsules per day, which increases their compliance by 70% compared to multiple injections or gavage after reconstitution of freeze-dried powder. It is particularly suitable for long-term management of chronic diseases such as metabolic syndrome. Capsules can be stably stored for 3 years under 25 ℃/60% RH conditions, while freeze-dried powder requires full cold chain transportation (2-8 ℃), reducing logistics costs by more than 60%.
